BaxGen Therapeutics Overview
- Year Founded
-
2024
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
BaxGen Therapeutics General Information
Description
Developer of small molecule therapeutics intended to aid cancer treatment by directly targeting the apoptosis pathway. The company offers a small-molecule activator of Bax, developed through deep insights into the apoptosis pathway, advanced structure-based and computational drug design, and biomarker-driven combination-targeting strategies, enabling clients to understand the complexities of apoptosis and identify critical molecular targets for therapeutic intervention.
Contact Information
Website
www.baxgentherapeutics.comCorporate Office
- 50 Pheasant Run
- Roslyn, NY 11576
- United States
Corporate Office
- 50 Pheasant Run
- Roslyn, NY 11576
- United States
BaxGen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 27-Apr-2026 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 19-Sep-2024 | Completed | Startup |
BaxGen Therapeutics FAQs
-
When was BaxGen Therapeutics founded?
BaxGen Therapeutics was founded in 2024.
-
Where is BaxGen Therapeutics headquartered?
BaxGen Therapeutics is headquartered in Roslyn, NY.
-
What industry is BaxGen Therapeutics in?
BaxGen Therapeutics’s primary industry is Drug Discovery.
-
Is BaxGen Therapeutics a private or public company?
BaxGen Therapeutics is a Private company.
-
What is BaxGen Therapeutics’s current revenue?
The current revenue for BaxGen Therapeutics is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process